# **Product** Data Sheet

## Pim-1 kinase inhibitor 9

Cat. No.: HY-163119

Molecular Formula:  $C_{36}H_{24}F_2N_4S_2$ Molecular Weight: 614.73

Target: Pim

Pathway: JAK/STAT Signaling

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

#### **BIOLOGICAL ACTIVITY**

Description

Pim-1 kinase inhibitor 9 (compound 8b) is a selective inhibitor against Pim-1 kinase with IC<sub>50</sub> value of 0.24 μM. Pim-1 kinase inhibitor 9 inhibitor 9 inhibitor 9 reveals antitumor activity<sup>[1]</sup>.

IC<sub>50</sub> & Target PIM1 PIM2

 $0.24~\mu M~(IC_{50})$   $10.53~\mu M~(IC_{50})$ 

In Vitro Pim-1 kinase inhibitor 9 inhibits the growth of breast cancer cells T47D with IC<sub>50</sub>values of 9.8 μM(8b , 48h) and 2.61 μM (8b ,

Pim-1 kinase inhibitor 9 inhibits the activities of Pim-1 kinase and Pim-2 kinase with IC50 values of 0.24  $\mu$ M (Pim-1 kinase) and 10.53  $\mu$ M (Pim-2 kinase),respectively<sup>[1]</sup>.

 $\label{eq:mce} \mbox{MCE has not independently confirmed the accuracy of these methods. They are for reference only.}$ 

Cell Cytotoxicity Assay<sup>[1]</sup>

Cell Line:	T47D
Concentration:	10 μΜ
Incubation Time:	48 h and 96 h
Result:	Exhibited cytotoxicity activity to T47D with IC <sub>50</sub> value of 9.8 μM (48 h) and 2.61μM (96h).

#### Cell Cycle Analysis<sup>[1]</sup>

Cell Line:	T47D
Concentration:	10 μΜ
Incubation Time:	48 h
Result:	Inhibited cell cycle at S phase.

In Vivo

Pim-1 kinase inhibitor 9 (1 mg/kg/once weekly for 3 weeks; i.p.) inhibits the growth of Ehrlich solid tumours in mice by promoting caspase-3 expression and inhibiting the expression of VEGF<sup>[1]</sup>.

 $\label{eq:mce} \mbox{MCE has not independently confirmed the accuracy of these methods. They are for reference only.}$ 

Animal Model:	swiss albino mice/Ehrlich solid carcinoma model $^{[1]}$
Dosage:	1 mg/kg
Administration:	i.p. injected once a week, for 3 weeks
Result:	Inhibited growth of Ehrlich solid tumours in mice.

### **REFERENCES**

[1]. Al-Sanea MM,et al., Design, synthesis and cytotoxic evaluation of novel bis-thiazole derivatives as preferential Pim1 kinase inhibitors with in vivo and in silico study. J Enzyme Inhib Med Chem. 2023 Dec;38(1):2166936.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com